EAY131 (MATCH): Molecular Analysis for Therapy Choice (MATCH)

About this Study

The purpose of this study is to see how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Sponsor Protocol ID:EAY131
IRB Number:2019-0241
Actively Enrolling
Phase 2
July 12, 2022
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
  • Child bearing women must have negative pregnancy test
  • Histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy¬†
  • Disease must be measurable on scan
  • Tumor tissue must be "rare variant" by MATCH analysis
  • Any prior therapy , radiotherapy, or major surgery must have been completed greater than or equal to 4 week prior to start of treatment
  • Patients with brain metastases or primary brain tumor must have completed treatment, surgery or radiation therapy greater than or equal to 4 weeks prior to start of treatment
  • Discontinued steroids greater than or equal to 1 week prior to registration to STEP 0

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials